https://orcid.org/0000-0001-9991-642X
Figures
Abstract
Background
The incidence of heart failure (HF) is increasing year by year, posing a great threat to human health. Although pharmacotherapy has been able to significantly prolong patient survival, pharmacotherapy for HF still has limitations due to its complex pathogenesis and considerable individual variability, there is a great need to explore complementary and alternative therapies to slow down the progression of HF. Danshen decoction is used to treat several cardiovascular diseases including HF, but the efficacy of stabilization is uncertain. This meta-analysis evaluated the clinical efficacy of Danshen Decoction for the treatment of HF.
Methods
The registration number assigned to this meta-analysis on the PROSPERO platform is CRD42022351918. Four databases were searched, and randomized controlled trials (RCTs) of Danshen decoction combined with conventional treatment (CT) of HF were screened, CT included medical treatments other than Danshen Decoction to which the patient was treated (including but not limited to angiotensin converting enzyme inhibitor, angiotensin receptor blocker, angiotensin receptor neprilysin inhibitors, β-blockers, diuretics, mineralcorticoid recept antagonist etc.). The clinical efficacy rate (CER), left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic diameter (LVESD), brain natriuretic peptide (BNP), N-terminal pro-B type natriuretic peptide (NT-proBNP) and hypersensitive C-reactive protein (hs-CRP) were included as outcome indicators. The GRADE grading scale was used to grade the above indicators. The Cochrane risk-of-bias tool and the Jadad quality scale were used to assess the methodological quality of RCTs. Finally, RevMan V.4.5 software was used for data synthesis, 95% confidence intervals (CI) for dichotomous data, risk ratios (RR), and mean differences (MD) for continuous variables were calculated, Chi-square and I2 were used for heterogeneity assessment.
Results
Nine RCTs with a total of 855 patients were included in this study, and all included RCTs had a low overall quality risk of bias and high quality of reported information. The results of the meta-analysis showed that compared with the use of CT, CER (%) was significantly improved due to Danshen decoction combined with CT (MD = 3.95, 95% CI [2.58, 6.04], P < 0.00001), LVEF (%) was significantly improved (MD = 5.46, 95% CI [5.32, 5.60], P < 0.00001), LVEDD (mm) was significantly reduced (MD = -5.27, 95% CI [-6.21, -4.32], P < 0.00001), LVESD (mm) was significantly reduced (MD = -4.60, 95% CI [-5.87, -3.32], P < 0.00001), BNP (pg/mL) was significantly reduced (MD = -88.61, 95% CI [-121.98, -55.24], P < 0.00001), NT-proBNP (pg/mL) was significantly decreased (SMD = -3.33, 95% CI [-5.92, -0.73], P = 0.01), hs-CRP (mg/L) was significantly decreased (MD = -2.73, 95% CI [-4.11, -1.34], P = 0.0001). The quality of the GRADE evidence for all outcomes was moderate to low and no RCTs reported adverse events.
Conclusion
Our research demonstrates that Danshen decoction is an effective and safe treatment option for HF. Nevertheless, considering the limitations of methodological and the quality of RCTs, more rigorous, large-scale, multicenter randomized clinical trials are needed to further evaluate the efficacy and safety of Danshen decoction in the treatment of HF patients.
Citation: Li Z, Liu M, Chen M, Luo G, Wu J, Mazhar M, et al. (2023) Clinical effect of Danshen decoction in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE 18(5): e0284877. https://doi.org/10.1371/journal.pone.0284877
Editor: Mustafa M. Ahmed, University of Florida, UNITED STATES
Received: October 8, 2022; Accepted: April 11, 2023; Published: May 5, 2023
Copyright: © 2023 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant date are within the manuscript and its Supporting Information files.
Funding: This work was supported by the National Natural Science Foundation of China (82074378), awarded to SY, the science and technology development fund, the Macau SAR (0098 / 2021 / A2), awarded to QW, the South West Medical University Project (2021zkqn143), awarded to ML, the national traditional Chinese medicine innovation and innovation team (zycxtd-c-202207), awarded to SY, Scientific Research Project of Traditional Chinese Medicine Bureau of Guangdong Province (20221354), awarded to MC, Shenzhen Science and Technology Program (JCYJ20210324111213038), awarded to MC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors declare that they have no conflicts of interest.
Abbreviations: BNP, Brain natriuretic peptide; CER, Clinical effective rate; CF, Cardiac function; CI, Confidence intervals; CRP, C-reactive protein; CT, Conventional Treatment; CVD, Cardiovascular diseases; HF, Heart failure; hs-CRP, Hypersensitive C-reactive protein; MD, mean difference; NT-proBNP, N-terminal pro-B type natriuretic peptide; OR, Odds ratios; PRISMA, The Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT, Randomized controlled trial; RD, Risk differences; RR, Risk ratios; SMD, Standardized mean difference; TCM, Traditional Chinese medicine; WHO, World Health Organization
Introduction
Heart failure (HF) is considered a new epidemic due to its increasing incidence and long duration [1]. In Summary of China Cardiovascular Health and Disease Report 2021, it is reported that the number of cardiovascular patients in China is about 330 million, of which 12.1 million are HF [2, 3], and the incidence rate increases with age [4]. The primary diseases of HF include myocardial infarction, myocarditis, hypertension and various risk factors that increase peripheral circulatory resistance leading to HF [5]. The main treatment methods include drug therapy and surgery. Pharmacotherapy includes angiotensin converting enzyme inhibitor, angiotensin receptor blocker, angiotensin receptor neprilysin inhibitors, β-blockers, diuretics, mineralcorticoid recept antagonist etc. [6], and surgical treatment includes heart transplantation and placement of cardiac assist devices [7, 8]. However, long-term drug treatment may cause side effects such as bradycardia, hypotension, and arrhythmia [9]. Surgical treatment also renders greater safety risks and impose strict restrictions on patients’ conditions [10]. The pathogenesis of HF is quite complex and there is considerable individual heterogeneity of the disease, there is a great need to explore complementary and alternative therapies to slow down the progression of HF [11].
Traditional Chinese medicine (TCM) has a history of more than 2,000 years in the treatment of HF, it was first recorded in the Yellow Emperor’s Canon of Internal Medicine (26 B.C.) [12, 13], and various prescriptions have been widely recognized for their therapeutic effects on HF after long-term clinical practice (Including Zhenwu decoction, Linggui Zhugan decoction, Wuling Powder, and Danshen decoction etc.) [14]. Danshen decoction is composed of Salvia miltiorrhiza Bge., Amomum villosum Lour, and Santalum album L [15, 16], and the details are shown in Table 1. Shifang Gekuo (AD 1801) recorded that it was mainly used for treating heartache and epigastric pain. At present, a large number of clinical and experimental studies have shown that Danshen decoction plays an important auxiliary function in the treatment of HF, and its therapeutic effects include improving cardiac function (CF), reducing peripheral vascular resistance, alleviating inflammation, etc. [17]. Until now, most of the published studies have witnessed consistent efficacy of Danshen decoction combined conventional treatment in the treatment of various cardiovascular diseases [18]. However, there is still a lack of evidence-based medical evaluation to prove the safety and efficacy of Danshen decoction in clinical treatment. Therefore, we conducted this meta-analysis to form an opinion on the treatment of HF with Danshen decoction and consider its prospects as an complementary and alternative therapy [19, 20].
In this paper, all studies related to Danshen decoction were searched, and inclusion-exclusion criteria was formulated to screen out all the eligible clinical studies. Afterwards, Review Manager 5.4 software was used to conduct a systematic and comprehensive review of the nine randomized controlled trials (RCTs). The clinical efficacy rate (CER) of Danshen decoction combined with conventional treatment (CT) in patients with HF, as well as the improvement of Danshen decoction combined with CT on CF, serological diagnostic indicators such as brain natriuretic peptide (BNP) [21], N-terminal pro-B type natriuretic peptide (NT-proBNP) and hypersensitive C-reactive protein (hs-CRP) in patients with HF were evaluated [22]. This study provides valuable evidence-based support for the clinical application of Danshen decoction in the treatment of cardiovascular diseases [23, 24].
Methods
This study used the preferred reporting item of the guidelines for systematic reviews and meta-analyses (PRISMA) and all research procedures were completed in accordance with PRISMA requirements [25, 26], and this study has been proofread by PRISMA 2020 Checklist, as shown in S1 Table. The details of our research have been registered in PROSPERO (https://www.crd.york.ac.uk/PROSPERO/) [27] with the registration number: CRD42022351918. The details of all studies refer to our previously published protocol [28].
Search strategy
Four databases, PubMed (https://pubmed.ncbi.nlm.nih.gov/), CNKI (https://www.cnki.net/), VIP (http://www.cqvip.com/) and Wanfang (https://www.wanfangdata.com.cn/) were used for retrieval, the retrieval time is from the establishment of the database to October 2022. The following keywords were used for individual or joint searches: randomized controlled trial, clinical controlled experiment, clinical observation, Danshen decoction, cardiovascular system, coronary heart disease, heart failure, ischemia-reperfusion injury, angina pectoris, heart valve disease, hypertension, pericardial disease, endocarditis, cardiac arrest, and sudden cardiac death. According to the above search method, RCTs related to the treatment of HF with Danshen decoction were manually screened and included in this study. The search strategy was presented as follows by taking PubMed as an example (S2 Table).
Type of studies
Inclusion criteria: (a) RCTs were related to Danshen decoction. (b) All included patients had to have one of the diagnoses with HF, Grading of disease should refer to the 2022 AHA/ACC/HFSA guideline for the management of heart failure (defined as B, C, or D stage) [29], or using the New York Heart Association (NYHA) grade to define cardiac function (defined as II, III or IV). (c) CER was defined as the primary outcome of RCTs, and the secondary outcomes were echocardiography and serological indicators. Exclusion criteria: (a) Duplicate articles. (b) Literature, other than English or Chinese language. (c) Grey literature and unpublished literature with unclear experimental data or incorrect results.
Data extraction
Two investigators (Ziyi Li and Mengnan Liu) independently screened titles and abstracts that might match studies. The full text of possible studies was then searched and summarized according to previously established inclusion-exclusion criteria. Data from clinical studies were then extracted independently by two investigators (Gang Luo and Hao Wu), including the title of each study, name of the first author, type of design, time of publication, sample size, grouping, mean age of patients included, primary diagnosis and diagnostic criteria, intervention measures in experimental group and control group, clinical feature and the result of laboratory detection, the dosage of administration, observation time, adverse drug reactions and reasons for withdrawal. Any discrepancies were discussed with the third investigator (Yu Zheng).
Methodological quality assessment
According to the Cochrane Collaboration Tool, the methodological quality of each included trial was scored by 2 investigators (Gang Luo and Yu Zheng). It consisted of seven areas: adequate sequence generation, hidden assignments, blinding participants and people, incomplete result data, selective reporting, and other deviations. There were three levels used to assess the quality of the methodology: “low risk of bias” (+), “high risk of bias” (-), and “unclear risk of bias” (?). If necessary, differences were discussed with a third investigator (Hao Wu) to reach a consensus conclusion.
Jadad scale tool was used to check the methodological quality of each included RCTs by two investigators (Gang Luo and Yu Zheng), the following four aspects were included: random sequence generation, randomization concealment, blinding, retreat and withdrawal [30]. Three levels were used to assess the quality of the method: Highly Compliant (2 points), Moderately Compliant (1 point), and Non-Compliant (0 points) [31], differences were discussed with the third investigator (Hao Wu) to reach consistent conclusions [32].
Data synthesis and analysis
Review Manager 5.4 was used for meta-analyses. Dichotomous data were expressed as risk ratios (RR), risk differences (RD), or odds ratios (OR) and continuous data as mean differences (MD) or standardized mean differences (SMD). We analysed statistical heterogeneity using the chi-square test (P > 0.10 for statistical significance) and quantified using the I2 statistic. If heterogeneity was not significant (P > 0.05, I2 < 50%), we performed a quantitative data synthesis (meta‐analysis) using a fixed‐effect model. Where heterogeneity was significant (P < 0.05), we analysed the cause to determine whether qualitative differences existed. If the clinical heterogeneity was not due to qualitative differences, we applied a random‐effects model [33–35].
Sensitivity analysis
If necessary, the sensitivity analysis will be used to assess the effect of each study on the random effects model. The sensitivity of the general combined effect of all outcome indicators will be analyzed by the exclusion method. In short, each study will be excluded and the rest will be re-analyzed to determine the stability of the results, which will be considered stable if the combined effects shown have not changed qualitatively.
Risk of bias across trials
When a meta-analysis contained at least 10 RCTs, the potential risk of bias across trials was examined by the funnel plots and Egger’s test. However, this meta-analysis contained less than 10 RCTs, so the funnel plot will not be considered [36, 37].
Quality of evidence
Three independent investigators assessed the risk of bias in each included trial using the GRADE (Grading, Evaluation, Development and Evaluation of Recommendations) approach [38–41]. Three levels of bias were used to assess the degree of bias in the trial by two investigators (Gang Luo and Yu Zheng) which included "low risk of bias" (None), "high risk of bias" (Serious), and "unspecified risk of bias" (No). The third investigator (Hao Wu) assessed for downgrade or promotion and divided into four grades: High (⊕⊕⊕⊕/A), Medium (⊕⊕⊕Ο/B), Low (⊕⊕ΟΟ/C) and extremely low (⊕ΟΟΟ/D). The risk of bias was mainly evaluated according to the following eight aspects: (a) Limitations of study design: there is an additional risk of misleading results due to flaws in the design or implementation of randomized controlled trials. (b) Inconsistency: estimates vary widely from study to study, the confidence intervals for each study are very narrow or do not overlap, the p-value for the heterogeneity test is small and the I2 value is large. (c) Indirect: population differences, intervention differences, outcome measures differences, and indirect evidence comparisons. (d) Imprecision: small sample size means less than 300 events per piece of evidence. (e) Publication bias: Reporting bias and poor robustness of results. (6) Large effect size: The effect size of the study is large and ideal, which can better improve the quality of the study. (f) There is a dose-effect relationship: the dose-effect relationship can describe the relationship between the results more clearly, which is of positive significance for research. (g) Negative bias. Negative bias makes the original bias return to normal, which also has a certain positive significance for research. Evidence will be lowered one level when the first five situations mentioned above occur. If there were bad trials, the evidence would be downgraded by two levels. When the last three situations mentioned above occur, the level of evidence should be appropriately raised and the level of evidence should be comprehensively assessed finally [42].
Results
Study identification
The study selection and identification process are shown in Fig 1. Initially, we collected 620 records via databases and the manual literature search, including Pubmed (n = 26), VIP (n = 234), WanFang (n = 139), CNKI (n = 221). Among these, 182 articles for duplication were discarded, and 290 grey literature and unpublished literature were removed. After reviewing the titles and abstracts, 120 articles that were not RCTs were removed. Subsequently, a total of 28 full-text articles were retrieved for further evaluation, of which 19 were excluded for the following reasons: RCTs without outcome indicators (n = 13) and RCTs without HF-related indicators study (n = 6). Finally, 9 RCTs were included in this study. Since this meta-analysis contained fewer than 10 RCTs, funnel diagram were not applicable, and the results of this meta-analysis may be potentially biased.
Characteristics of the included RCTs
The basic characteristics of the nine included RCTs are shown in Table 2. Overall, all RCTs used a randomized controlled design (one experimental group and one control group), we identified 855 participants from 9 articles with 429 cases in the experimental group and 426 cases in the control group. All the included studies were published in Chinese, and all RCTs had small sample sizes, ranging from 30 to 87 people. The average age of patients participating in the study was 54 to 63 years old. HF was first diagnosed in 6 RCTs [43–48], and coronary heart disease was the first diagnosis in the other 2 RCTs [49, 50], and cardiomyopathy was the first diagnosis in the remaining one, According to the latest definitions and diagnostic criteria for heart failure, combined with the patient’s clinical manifestations and echocardiographic indicators, all patients included in the study met the diagnostic criteria for heart failure [51]. For the intervention, the patients in the experimental group received different doses of Danshen decoction combined with CT (Doses range from 200 mL/bid to 400 mL/bid), and patients in the control group received CT alone. CER was identified as the primary outcome. CF including left ventricular ejection fraction (LVEF) [52], left ventricular end-diastolic dimension (LVEDD), and left ventricular end-systolic diameter (LVESD) [53], and serological indicators including BNP, NT-proBNP, and hs-CRP, were identified as secondary outcomes [54]. The duration of treatment varied from 2 weeks to 2 months.
Evaluation of methodological quality
The methodological quality of the included studies is shown in Figs 2 and 3. Nine RCTs [43–51] mentioned that sequence generation was illustrated by randomization or by random number tables and plots and rated as low risk concerning overall quality. Five RCTs [44–46, 50, 51] mentioned random assignment concealment and analyzed specific implementation measures considered to have low random bias, and the remaining three RCTs [43, 47, 55] did not clearly describe assignment concealment and were defined as unclear. None of the nine RCTs described the blinding of participants and personnel, the performance bias was considered unclear. The blinding of outcome assessment in two RCTs [43, 48] was well described and considered to have low random sequence bias, while the remaining RCTs were poorly defined as unclear. All nine RCTs completely reported the CER and LVEF as outcomes, considered to have low attrition bias and reporting bias. Other biases (including but not limited to selection bias, information bias, confounding bias, etc.) are considered to exist in two RCTs [45, 50] due to unclear descriptions. Taken together, all RCTs were considered not to be at high risk of bias. Table 2 and S3 Table were presented for the Jadad scores of all RCTs.
Primary outcome
CER.
A total of nine studies [43–51] with 855 patients, including 426 cases in the control group and 429 cases in the experimental group. Compared with the CT alone, the CER (%) has been significantly improved due to the combination of Danshen decoction and CT. There was statistical homogeneity for this outcome (I2 = 0%), and the fixed-effects model was applied (MD = 3.95, 95% CI [2.58, 6.04], P < 0.00001) (Fig 4).
Second outcomes
LVEF.
A total of nine studies [43–51] with 855 patients, including 426 cases in the control group and 429 cases in the experimental group. Compared with CT alone, the LVEF (%) was significantly improved due to the combination of Danshen decoction and CT. There was statistical homogeneity for this outcome (I2 = 0% < 50%), and the fixed-effects model was applied (MD = 5.46, 95% CI [5.32, 5.60], P < 0.00001) (Fig 5).
LVEDD.
A total of four studies [43, 44, 48, 51] with 172 patients, including 86 in the control group and 86 in the experimental group. Compared with CT alone, the LVEDD (mm) was significantly decreased due to the combination of Danshen decoction and CT, heterogeneity existed across the studies (I2 = 81%, P = 0.001), a random-effects model was applied (MD = -4.39, 95% CI [-6.22, -2.55], P < 0 .00001). In order to analyze the reasons for the high heterogeneity, a subgroup analysis was performed after checking the specific information of the RCTs. After rechecking the specific information of the included research subjects, it was found that the HF grades of the subjects in three RCTs [43, 48, 51] were grades II to III, while the HF grades of the subjects in the one RCT [44] were grades III to IV, the cause of high clinical heterogeneity is considered to be related to the severity of the disease, after excluding this study, there was statistical homogeneity for this outcome (I2 = 48%), and the fixed-effects model was applied (MD = -5.27, 95% CI [-6.21, -4.32], P < 0.00001) (Fig 6).
LVESD.
A total of three studies [43, 48, 50] with 309 patients, including 153 in the control group and 156 in the experimental group. Compared with CT alone, the LVESD (mm) was significantly decreased due to the combination of Danshen decoction and CT. There was statistical homogeneity for this outcome (I2 = 0%), and the fixed-effects model was applied (MD = -4.60, 95% CI [-5.87, -3.32] P < 0.00001) (Fig 7).
BNP.
A total of two studies [45, 46] with 170 patients, including 85 in the control group and 85 in the experimental group. Compared with CT alone, BNP (pg/mL) was significantly decreased due to the combination of Danshen decoction and CT, and heterogeneity existed across the studies (I2 = 83%, P < 0.00001), the random-effect model was applied (MD = -88.61, 95% CI [-121.98, -55.24], P < 0.00001) (Fig 8). There were significant differences in the age and course of treatment of the subjects of this clinical study, which were initially considered to be clinical heterogeneity.
NT-proBNP.
A total of 3 studies [44, 47, 50] involving 267 patients, including 133 cases in the control group and 134 cases in the experimental group. Compared with CT alone, the NT-proBNP (pg/mL) was significantly decreased due to the combination of Danshen decoction and CT, and heterogeneity existed across the studies (I2 = 98% < 50%, P < 0.00001), the random-effect model was applied (SMD = -3.33, 95% CI [-5.92, -0.73], P = 0.01) (Fig 9). Sensitivity analysis showed that no obvious heterogeneity was found after removing any study. There were differences in the course of disease, medication time and dose of the subjects in the RCTs included in this group, which were initially considered to be clinical heterogeneity.
hs-CRP.
A total of three studies [44, 50, 51] involving 303 patients, including 151 cases in the control group and 152 cases in the experimental group. Compared with CT alone, the hs-CRP (mg/L) was significantly decreased due to the combination of Danshen decoction and CT, and heterogeneity existed across the studies (I2 = 98% > 50%, P < 0.00001), the random-effect model was applied (MD = -2.73, 95% CI [-4.11, -1.34], Z = 3.85, P = 0.0001) (Fig 10). There were significant differences in the first diagnosis and disease course of the three RCTs in this group, and they could not be improved according to the acute and non-acute subgroups of the disease, which was initially considered to be clinical heterogeneity.
Quality of evidence
In this study, the quality of evidence for all included RCTs was downgraded by one grade because the risk of methodological bias was unclear. With the exception of CER, LVEF, LVESD and hs-CRP, the number of patients included in LVEDD, BNP and NT-probNP was no more than 300, so the quality of evidence for these outcomes was downgraded by one grade. The quality of the evidence suggests that the escalation did not apply to any outcome. Overall, the quality of evidence was moderate for CER, LVEF, LVESD and hs-CRP, and low for LVEDD, BNP and NT-proBNP (Table 3).
Discussion
Overall, this study has the following characteristics: (a) This is a PROSPERO-registered meta-analysis, and the analysis method will be published and updated in time for further research. (b) Electronic and manual retrieval methods were used to ensure that the included RCTs are relevant for meta-analysis. (c) Our confidence in the findings was further increased by performing robust sensitivity analyses and reliable subgroup analyses.
As revealed in this meta-analysis, CER is a comprehensive evaluation index derived from multiple clinical indicators and patient subjective rating scales, and was defined as the primary outcome in this study [56]. All the RCTs included in the meta-analysis obtained satisfactory CERs from the data of their respective studies, and achieved statistically significant heterogeneity, which means that the patient’s various heart failure indicators have been greatly improved and affirmed the effect of Danshen decoction combined with CT in the treatment of HF [57]. In terms of objective indicators, cardiac color doppler ultrasound is mainly used to evaluate the changes of CF in patients. Among the data measured by multiple cardiac color doppler ultrasound, LVEF is considered to be the most valuable indicator. In this study, LVEF was included in all RCTs, and the first diagnosis of these patients included HF, myocardial infarction and coronary heart disease. The results showed that Danshen decoction combined with CT could significantly improve the LVEF of patients to treat HF. In addition, LVEDD and LVESD in each experimental group as cardiac color doppler ultrasound observation data were significantly reduced under the treatment of Danshen decoction combined with CT, and showed statistically significant heterogeneity, which further proved the clinical effect of Danshen decoction. BNP and NT-proBNP reflect the severity of HF, while hs-CRP reflects the possible inflammatory response in the patient. The results of the meta-analysis showed that all serological indexes could be significantly reduced under the treatment of Danshen decoction combined with CT, but the heterogeneity was obvious, and no statistically significant heterogeneity could be obtained through sensitivity analysis and subgroup analysis. The severity of the disease in RCTs was considered to be the cause of the high heterogeneity, and more randomized controlled trials facilitated more satisfactory heterogeneity results.
TCM is characterized by multiple pharmacodynamic material basis, multiple therapeutic targets and low side effects [55, 58]. A large number of pharmacological studies have verified that Danshen decoction has the functions of anti-myocardial fibrosis, protecting myocardial cells, maintaining the ultrastructure of the heart, and improving coronary blood flow [59, 60], however, there are few reports in the clinic studies that significant adverse reactions of Danshen decoction occurred during the use of patients. This meta-analysis verifies that Danshen decoction as a complementary therapy has a definite effect on the improvement of HF symptoms, as well as a significant effect on patients with different cardiovascular disease-induced symptoms of HF, and none of the included RCTs reported adverse effects. Therefore, Danshen decoction is an effective and safe complementary therapy for HF with great clinical application prospects.
Limitations and suggestions
Limitations.
First of all, among the RCTs included in this study, only 1 RCT reported no adverse reactions during the use of Danshen decoction, and the remaining 8 RCTs reported no adverse reactions. As far as we know, the safety evaluation of drugs includes toxicological studies, contraindications, precautions, drugs in special groups, drug interactions and adverse reactions. At present, the toxicology studies of Danshen decoction show that no obvious side effects are found in acute and chronic toxicological experiments, and Danshen decoction is a low-toxic prescription [61]. By reviewing the clinical studies of Danshen decoction, there were no obvious adverse effects of Danshen decoction as adjuvant therapy or combination therapy, and any contraindications and special population were found. Therefore, We have a positive assessment of the security of Danshen decoction. However, more rigorous evidence-based medical evidence and more extensive clinical studies are still needed to demonstrate the safety of Danshen decoction [62]. However, systematic reports of adverse reactions and other safety assessments are still lacking in clinical studies. Secondly, in terms of RCT quality evaluation, only 2 of the 9 RCTs had higher Jadad scores and GRADE grades, and the remaining RCTs had more or less research bias, for example, the logic of experimental design, the randomness of experimental object selection, comprehensiveness of experimental result selection and avoidance of other bias cannot be fully reflected in RCTs [63]. All the participants in the included studies were Chinese, and the uncertainty of racial and regional differences were high [64]. Finally, as a classic TCM formulation, Danshen decoction currently does not have the production process and quality control standards formulated by the International Organization for Standardization, therefore, during the clinical research, there may be differences in the Danshen decoction prepared by different hospitals or individuals, and there is no RCT study using Danshen decoction alone as the treatment of the experimental group, which further increases the limitations of this study [65, 66].
Suggestions.
In order to improve the strength of evidence for the treatment of cardiovascular diseases with Danshen decoction, future clinical research should focus on the following aspects [67]: (a) With the transformation of the human disease spectrum and modern medical model, Danshen decoction has been more widely used in the clinical treatment of HF in the form of complementary therapy in the future, the influence of Danshen decoction on the long-term prognosis of the disease and adverse reactions should be clarified in order to further verify its effectiveness and safety. (b) More multi-center, larger randomized controlled trials are required to improve the quality of clinical research and the strength of evidence, rigorous random allocation methods and blinding operations are needed to be adopted, wider research participants and more comprehensive outcome measures should be selected [68]. (c) The quality standard of Danshen decoction should be determined to reduce the clinical bias in drug intervention, the analysis of active components of Danshen decoction needs to be deeply studied, and the research on the mechanism of action of Danshen decoction on HF and the research on pharmacodynamic substances should be widely carried out [69].
Conclusions
Danshen decoction combined with conventional treatment significantly improved the clinical effective rate, cardiac function, and serological indicators in heart failure patients, and there were no adverse events reported due to this combination therapy, indicating that Danshen decoction as an adjuvant therapy is a promising treatment option for heart failure. However, given the limitations of RCTs in this study, more rigorous, larger and multicenter randomized clinical trials are guaranteed to further evaluate the efficacy and safety of Danshen decoction for patients with heart failure.
Acknowledgments
I would like to thank my supervisor Dr. Mengnan Liu for his academic guidance in Southwest Medical University. I would also like to thank the corresponding authors Prof. Qibiao Wu and Prof. Sijin Yang and the team of Dr. Mengnan Liu (Jiao Wu and Fang Yang) for their support for my research work.
References
- 1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93: 1137–1146. pmid:17699180
- 2. Kurmani S, Squire I. Acute Heart Failure: Definition, Classification and Epidemiology. Curr Heart Fail Rep. 2017;14: 385–392. pmid:28785969
- 3. Wang H, Chai K, Du M, Wang S, Cai J-P, Li Y, et al. Prevalence and Incidence of Heart Failure Among Urban Patients in China: A National Population-Based Analysis. Circ Heart Fail. 2021;14: e008406. pmid:34455858
- 4. The Writing Committee of the Report on Cardiovascular Health and Diseases in China 2021. Overview of the China Cardiovascular Health and Disease Report 2021. Cardiovascular Research in China. 2022;20: 577–596.
- 5. Yang X, Li J, Hu D, Chen J, Li Y, Huang J, et al. Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China). Circulation. 2016;134: 1430–1440. pmid:27682885
- 6. Tanai E, Frantz S. Pathophysiology of Heart Failure. Compr Physiol. 2015;6: 187–214. pmid:26756631
- 7. Liang B, Zhao Y-X, Zhang X-X, Liao H-L, Gu N. Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovasc Diabetol. 2020;19: 55. pmid:32375806
- 8. McMahon SR, Ades PA, Thompson PD. The role of cardiac rehabilitation in patients with heart disease. Trends Cardiovasc Med. 2017;27: 420–425. pmid:28318815
- 9. Fragasso G. Editorial Commentary: Drug dosing optimization in heart failure: Need of a multidimensional approach (and skilled heart failure specialists). Trends Cardiovasc Med. 2021;31: 117–118. pmid:32014369
- 10. Gude NA, Sussman MA. Cardiac regenerative therapy: Many paths to repair. Trends Cardiovasc Med. 2020;30: 338–343. pmid:31515053
- 11. Truby LK, Rogers JG. Advanced Heart Failure: Epidemiology, Diagnosis, and Therapeutic Approaches. JACC Heart Fail. 2020;8: 523–536. pmid:32535126
- 12. Xin Y, Dai Y-Y, Zhang X-W, Yang H-X, Hou A-L, Yang K, et al. A brief discussion on evidence-based clinical research of traditional Chinese medicine. Ann Palliat Med. 2021;10: 12937–12944. pmid:32819138
- 13. Li T, Zhao Y. Talking about the mechanism of heart decay from huangdi neijing. Henan Traditional Chinese Medicine. 2013;33: 1182.
- 14. Fu S, Zhang J, Gao X, Xia Y, Ferrelli R, Fauci A, et al. Clinical practice of traditional Chinese medicines for chronic heart failure. Heart Asia. 2010;2: 24–27. pmid:27325938
- 15. Kong L, Du G. Modern research progress of Danshen Decoction. Chinese Journal of Pharmacology and Toxicology. 2019;33: 709.
- 16. Chen H, Sun M, An R, Ni Q. Study on the application of Danshen Yin in cardiovascular disease. Jilin traditional Chinese Medicine. 2013;33: 27–30.
- 17. Liu M, Yuan G, Luo G, Guo X, Chen M, Yang H, et al. Network Pharmacology Analysis and Experimental Verification Strategies Reveal the Action Mechanism of Danshen Decoction in Treating Ischemic Cardiomyopathy. Evid Based Complement Alternat Med. 2022;2022: 7578055. pmid:35722148
- 18. Hao P, Jiang F, Cheng J, Ma L, Zhang Y, Zhao Y. Traditional Chinese Medicine for Cardiovascular Disease: Evidence and Potential Mechanisms. J Am Coll Cardiol. 2017;69: 2952–2966. pmid:28619197
- 19. Špinar J, Špinarová L, Vítovec J. Pathophysiology, causes and epidemiology of chronic heart failure. Vnitr Lek. 2018;64: 834–838.
- 20. Tomasoni D, Adamo M, Lombardi CM, Metra M. Highlights in heart failure. ESC Heart Fail. 2019;6: 1105–1127. pmid:31997538
- 21. Oikonomou E, Zografos T, Papamikroulis G-A, Siasos G, Vogiatzi G, Theofilis P, et al. Biomarkers in Atrial Fibrillation and Heart Failure. Curr Med Chem. 2019;26: 873–887. pmid:28875838
- 22. Kuster N, Huet F, Dupuy A-M, Akodad M, Battistella P, Agullo A, et al. Multimarker approach including CRP, sST2 and GDF-15 for prognostic stratification in stable heart failure. ESC Heart Fail. 2020;7: 2230–2239. pmid:32649062
- 23. Benz AP, Aeschbacher S, Krisai P, Moschovitis G, Blum S, Meyre P, et al. Biomarkers of Inflammation and Risk of Hospitalization for Heart Failure in Patients With Atrial Fibrillation. J Am Heart Assoc. 2021;10: e019168. pmid:33843247
- 24. Magnussen C, Blankenberg S. Biomarkers for heart failure: small molecules with high clinical relevance. J Intern Med. 2018;283: 530–543. pmid:29682806
- 25. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6: e1000100. pmid:19621070
- 26. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. pmid:33782057
- 27. Cheng B, Chen P, Deng Y. Efficacy and safety of integrated traditional Chinese medicine and standard Western medicine for patients with acute coronary syndrome: protocol for a systematic review and meta-analysis. Ann Palliat Med. 2021;10: 5763–5766. pmid:34107713
- 28. Liu M, Wang R, Li Z, Mazhar M, Luo G, Yang S. Danshen decoction in the treatment of heart failure: A systematic review and meta-analysis protocol of randomized controlled trials. Medicine (Baltimore). 2022;101: e30698. pmid:36123860
- 29. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145: e876–e894. pmid:35363500
- 30. Mohsina S, Gurushankari B, Niranjan R, Sureshkumar S, Sreenath GS, Kate V. Assessment of the quality of randomized controlled trials in surgery using Jadad score: Where do we stand? J Postgrad Med. 2022. pmid:35417999
- 31. Palys KE, Berger VW. A note on the jadad score as an efficient tool for measuring trial quality. J Gastrointest Surg. 2013;17: 1170–1171. pmid:23233271
- 32. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17: 1–12. pmid:8721797
- 33. Chen H, Yao X, Li T, Lam CW-K, Zhang H, Wang J, et al. Compound Kushen injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A protocol for meta-analysis of randomized clinical trials following the PRISMA guidelines. Medicine (Baltimore). 2019;98: e18552. pmid:31876753
- 34. Chen H, Yao X, Liu Z, Li T, Xu C, Wang J, et al. Efficacy and safety of Shenqi Fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019;98: e17350. pmid:31574877
- 35. Wang X, Liu Z, Sui X, Wu Q, Wang J, Xu C. Elemene injection as adjunctive treatment to platinum-based chemotherapy in patients with stage III/IV non-small cell lung cancer: A meta-analysis following the PRISMA guidelines. Phytomedicine. 2019;59: 152787. pmid:31005810
- 36. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10: ED000142. pmid:31643080
- 37. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315: 629–634. pmid:9310563
- 38. Balshem H, Helfanda M, J.Schunemann H, D.Oxman A, Kunz R, Brozek J, et al. Grade Guide: III Evidence quality classification. Chinese Journal of evidence based medicine. 2011;11: 451–455.
- 39. Guyatt G D.Oxman A, Akl E, Kunz R, Vist G, Brozek J, et al. Grade Guide: I Introduction—grade evidence summary table and result summary table. Chinese Journal of evidence based medicine. 2011;11: 437–445.
- 40. Guyatt G H., Oxman A D., Kunz R, Atkins D, Brozek J, Vist G, et al. Grade Guide: II Build problems and identify important results. Chinese Journal of evidence based medicine. 2011;11: 446–450.
- 41. Guyatt G H., Oxman A D., Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. Grade Guide: Ⅳ Evidence quality classification—limitations of the study (risk of bias). Chinese Journal of evidence based medicine. 2011;11: 456–463.
- 42. He Y, Guo X, May BH, Zhang AL, Liu Y, Lu C, et al. Clinical Evidence for Association of Acupuncture and Acupressure With Improved Cancer Pain: A Systematic Review and Meta-Analysis. JAMA Oncol. 2020;6: 271–278. pmid:31855257
- 43. Cai X, Zhang X, Wang F. Curative effect of Danshen Decoction on chronic pulmonary heart disease with heart failure and its effect on blood gas index and cardiac function. Zhejiang Journal of traditional Chinese Medicine. 2015;50: 555–556.
- 44. Guo Q, Zhou S. Effect of modified chaiting Danshen Decoction on heart failure of coronary heart disease (syndrome of qi stagnation, blood stasis and water stagnation) and its effect on 24h urine volume and AVP. Sichuan Traditional Chinese Medicine. 2021;39: 64–68.
- 45. Wang X, Zhang L, Na D, Jiang H. Clinical study on the treatment of chronic heart failure with modified Danshen Decoction and Zhenwu Decoction. Journal of cardio cerebrovascular diseases with integrated traditional Chinese and Western Medicine. 2019;17: 2624–2626.
- 46. Wei G, Yang X. Effect of Shengmai Powder and Danshen Decoction Combined with western medicine on chronic heart failure. Shaanxi traditional Chinese Medicine. 2018;39: 1702–1704+1708.
- 47. Wu Y, Jiang S, Xu Y. Clinical observation of Zhenwu decoction combined with Danshen Decoction in treating chronic heart failure of Yang deficiency and blood stasis type. Guangming traditional Chinese Medicine. 2020;35: 2885–2887.
- 48. Xu J, Kong L. Clinical effect of Danshen Decoction Combined with Xuefu Zhuyu Decoction on chronic heart failure. Cardiovascular disease prevention and control knowledge. 2021;11: 46–48.
- 49. Liu R. Clinical observation on treatment of angina pectoris of coronary heart disease with ginseng decoction, Gualou xiebanxia Decoction and Danshen Decoction. Journal of practical Chinese Medicine. 2018;34: 18–20.
- 50. Xue E, Li H, Liu C. Effects of modified Danshen Decoction Combined with tegrilol on cardiac function, hs CRP, NT proBNP and Fib in patients with coronary heart disease. Western Traditional Chinese Medicine. 2019;32: 83–85.
- 51. Sheng Y, Shen L. Effect of Shengmai Powder and Danshen Yin on diabetes cardiomyopathy and myocardial fibrosis. New traditional Chinese Medicine. 2022;54: 62–66.
- 52. Pfeffer MA, Shah AM, Borlaug BA. Heart Failure With Preserved Ejection Fraction In Perspective. Circ Res. 2019;124: 1598–1617. pmid:31120821
- 53. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14: 591–602. pmid:28492288
- 54. Rude RE, Grossman W, Colucci WS, Benotti JR, Carabello BA, Wynne J, et al. Problems in assessment of new pharmacologic agents for the heart failure patient. Am Heart J. 1981;102: 584–590. pmid:7270403
- 55. Xu Q, Bauer R, Hendry BM, Fan T-P, Zhao Z, Duez P, et al. The quest for modernisation of traditional Chinese medicine. BMC Complement Altern Med. 2013;13: 132. pmid:23763836
- 56. Allen LA, Spertus JA. End points for comparative effectiveness research in heart failure. Heart Fail Clin. 2013;9: 15–28. pmid:23168314
- 57. Wittenbecher C, Eichelmann F, Toledo E, Guasch-Ferré M, Ruiz-Canela M, Li J, et al. Lipid Profiles and Heart Failure Risk: Results From Two Prospective Studies. Circ Res. 2021;128: 309–320. pmid:33272114
- 58. Xie R, Xia Y, Chen Y, Li H, Shang H, Kuang X, et al. The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Pharmacol Res. 2020;160: 105178. pmid:32889127
- 59. Ren Y, Yang L, Zhao M, Zheng G, Xu J, Yang C, et al. Protective effect of danshenyin preconditioning on myocardial ischemia-reperfusion injury in rats. Journal of modern integrated traditional Chinese and Western Medicine. 2021;30: 2509–2512+2560.
- 60. Li Y, Guo J, Zhao L. Study on the mechanism of danshenyin in treating angina pectoris based on network pharmacology. World traditional Chinese Medicine.: 1–8.
- 61. Lu M, Jin C, Zheng C, Zhou X. Toxicological Experimental Study on Danshen Zhizhu Drink. Jiangxi Traditional Chinese Medicine. 2009;40: 53–55.
- 62. Li S, Zhang H, Yu Y. Advances in pharmacological research and clinical application of Danshen Decoction. Traditional Chinese Medicine Information. 2017;34: 117–120.
- 63. Zhang J, Li Y, Zhang B, Chen K, Wang Q, Li Z, et al. Evidence-based traditional Chinese medicine research: Beijing Declaration. J Evid Based Med. 2020;13: 91–92. pmid:32470228
- 64. Wang J, Wong Y-K, Liao F. What has traditional Chinese medicine delivered for modern medicine? Expert Rev Mol Med. 2018;20: e4. pmid:29747718
- 65. Wang Y-Y, Wang Z-F. [Future development of evidence based traditional Chinese medicine:flat way to truth and kindness]. Zhongguo Zhong Yao Za Zhi. 2019;44: 2893–2895. pmid:31602830
- 66. Zhang J-H, Li Y-P, Zhang B-L. Evidence-based Chinese medicine: theory and practice. Zhongguo Zhong Yao Za Zhi. 2018;43: 1–7. pmid:29552804
- 67. McMurray JJV, Packer M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine. Circulation. 2021;143: 875–877. pmid:33378214
- 68. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138: 861–870. pmid:29792299
- 69. Gupta AK, Tomasoni D, Sidhu K, Metra M, Ezekowitz JA. Evidence-Based Management of Acute Heart Failure. Can J Cardiol. 2021;37: 621–631. pmid:33440229